MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
17.49
+0.46 (2.70%)
At close: Mar 9, 2026, 4:00 PM EDT
17.15
-0.34 (-1.94%)
After-hours: Mar 9, 2026, 5:03 PM EDT
Company Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally.
The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers.
MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd.
| Country | Israel |
| Founded | 2000 |
| IPO Date | Mar 20, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 111 |
| CEO | Ofer Gonen |
Contact Details
Address: 42 Hayarkon Street Yavne, 8122745 Israel | |
| Phone | 972 7 797 14100 |
| Website | mediwound.com |
Stock Details
| Ticker Symbol | MDWD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001593984 |
| CUSIP Number | M68830104 |
| ISIN Number | IL0011316309 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Ofer Gonen B.Sc. | Chief Executive Officer |
| Hani Luxenburg | Chief Financial Officer |
| Dr. Shmulik Hess Ph.D. | Chief Operating Officer and Chief Commercial Officer |
| Yaron Meyer Adv. | Executive Vice President, General Counsel and Corporate Secretary |
| Dr. Ety Klinger MBA, Ph.D. | Chief Medical Officer |
| Dr. Liron Gal | Vice President of Manufacturing Science and Technology |
| Barry J. Wolfenson | Executive Vice President of Strategy and Corporate Development |
| Hagit Mashiach | Vice President of Human Resources |
| Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Senior Vice President of Global Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 5, 2026 | 6-K | Report of foreign issuer |
| Feb 19, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 11, 2026 | SCHEDULE 13G/A | Filing |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |
| Jan 15, 2026 | 6-K | Report of foreign issuer |
| Jan 12, 2026 | 6-K | Report of foreign issuer |